Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Nov;85(5):389-97.
doi: 10.1007/s00223-009-9294-y. Epub 2009 Oct 9.

Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women

Yoon-Sok Chung  1 , Sung-Kil Lim, Ho-Yeon Chung, In-Kyu Lee, Il-Hyung Park, Ghi-Su Kim, Yong-Ki Min, Moo-Il Kang, Dong-Jin Chung, Yong-Ki Kim, Woong Hwan Choi, Min Ho Shong, Ji-Hyun Park, Dong-Won Byun, Hyun-Koo Yoon, Chan Soo Shin, Yil-Seob Lee, Nam-Hee Kwon
Affiliations
Randomized Controlled Trial

Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women

Yoon-Sok Chung et al. Calcif Tissue Int. 2009 Nov.

Abstract

Patient preferences, convenience, and bone turnover markers were evaluated for the monthly ibandronate over the weekly risedronate regimen in Korean postmenopausal osteoporotic women. This was a 6-month, prospective, randomized, open-label, multicenter study with a two-period and two-sequence crossover treatment design. After a 30-day screening period, eligible participants with postmenopausal osteoporosis were randomized to receive either monthly oral ibandronate 150 mg for 3 months followed by weekly oral risedronate 35 mg for 12 weeks (sequence A) or the same regimen in reverse order (sequence B). Patient preference and convenience were evaluated by questionnaire. The changes in serum C-telopeptide after 3 months of treatment were analyzed. A total of 365 patients were enrolled in this study (sequence A 182, sequence B 183). Of patients expressing a preference (83.4%), 74.8% preferred the monthly ibandronate regimen over the weekly regimen (25.2%). More women stated that the monthly ibandronate regimen was more convenient (84.2%) than the weekly regimen (15.8%). There was no significant difference in the change in bone turnover marker between the two treatments. The two regimens were similarly tolerable. There were fewer adverse events in the monthly ibandronate group compared to the weekly risedronate group in terms of gastrointestinal side effects (nausea and abdominal distension). This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design and randomization schedule
Fig. 2
Fig. 2
Disposition of subjects
Fig. 3
Fig. 3
Patient preferences for ibandronate monthly dosing over risedronate weekly dosing, including patients who did not express a preference for one treatment
Fig. 4
Fig. 4
Patient preferences and reasons for preference (excluding patients who did not state a preference for one treatment). Patients could provide more than one reason for preferring a particular regimen
Fig. 5
Fig. 5
Patients who found ibandronate monthly dosing more convenient than risedronate weekly dosing, including patients who did not express an opinion about convenience for one treatment
See this image and copyright information in PMC

References

    1. Cooper C, Compion G, Melton LJ. Hip fractures in the elderly: a worldwide projection. Osteoporos Int. 1992;2:285–289. doi: 10.1007/BF01623184. - DOI - PubMed
    1. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–1249. doi: 10.1359/JBMR.040325. - DOI - PubMed
    1. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc. 2005;80:379–388. doi: 10.4065/80.3.379. - DOI - PubMed
    1. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–1352. doi: 10.1001/jama.282.14.1344. - DOI - PubMed
    1. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437–1443. doi: 10.1056/NEJM199511303332201. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources